Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Inclusion Criteria: * Written informed consent should be signed before implementing any trial-related procedures * Male or female, 18 years old ≤ age ≤ 75 years old * Histopathologically or cytologically diagnosed as locally advanced intrahepatic cholangiocarcinoma * No previous systemic treatment, More than 6 months after the end of postoperative adjuvant therapy was allowed * Expected survival time \> 3 months * At least ≥ 1 measurable lesions per RECIST 1.1 * ECOG PS scores 0-2 * Sufficient organ and bone marrow function * Urine or serum pregnancy test is negative Exclusion Criteria: * Suffered from other malignant tumors in the past 5 years (except Radical basal cell carcinoma of the skin squamous carcinoma of the skin and/or radical resected carcinoma in situ) * Ampullary tumor * Received treatment from other clinical trials within 4 weeks before the first dose * Received any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA4 antibody, or other immunotherapy * Suffered from severe cardiovascular disease within 12 months before enrollment, such as symptomatic coronary heart disease, congestive heart failure ≥ Grade II, uncontrolled arrhythmia, and myocardial infarction * Uncontrollable pleural effusion, pericardial effusion or ascites * Use steroids or other systemic immunosuppressive therapies 4 weeks before enrollment * Allergic reactions to the drugs used in this study * HIV antibody positive, active hepatitis B or C (HBV, HCV) * Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation * other conditions that the investigator deems inappropriate for enrollment.